Volume 2012, Issue 2
  • ISSN: 2305-7823
  •  E-ISSN:  Will be obtained soon
This item has no full text

There is no abstract available for this article.


Article metrics loading...

Loading full text...

Full text loading...



  1. Pieske BM ALDO-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure. European Society of Cardiology 2012 Congress, Munich, Germany at < http://www.eurekalert.org/pub_releases/2012-08/esoc-tas082,612.php>
  2. ElGuindy, A. & Yacoub, M. Review article: Heart Failure with Preserved Ejection Fraction. Global Cardiology Science and Practice 2012–10
  3. B. a Borlaug, W.J Paulus. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European heart journal. 2011; 32::6709
    [Google Scholar]
  4. A.S. Desai, et al.. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American heart journal. 2011; 162::96697.e10
    [Google Scholar]
  5. S.D. Solomon, et al.. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet. 2012 :doi:10.1016/S0140–6736(12)61,227-6
    [Google Scholar]
  6. M.P. Lefkowitz. LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension. BMC Pharmacology. 2011; 11::O3
    [Google Scholar]
  7. A. Martinez-Rumayor, A.M. Richards, J.C. Burnett, J.L. Januzzi. Biology of the natriuretic peptides. The American journal of cardiology. 2008; 101::38
    [Google Scholar]
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error